Von Willebrand disease (VWD) is a genetic bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor (VWF), a protein involved in blood clotting. This deficiency can lead to prolonged bleeding, easy bruising, and excessive bleeding after injury or surgery. Treatment typically involves medications to increase VWF levels or enhance clotting, along with measures to prevent and manage bleeding episodes, such as desmopressin and clotting factor concentrates.
Patients are the experts in their condition and advocacy groups provide a platform for patient voices. Working directly with these communities is the key to pushing research forward in an inclusive way.
We’ve committed to having 500,000 conversations in the next three years, to equip ourselves and our Pharma partners with the insights needed to increase predictability.
Read more...
The ever-growing investment in advocacy doesn’t appear to be slowing down, and research is certainly seeing the benefits. Which at the end of the day, means better patient care and more options for patients.
Read more...
We’re ready to keep forming links between our Advocacy friends and Pharma partners, so these fruitful relationships continue to evolve beyond the study-to-study view.
Read more...